Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients

H. Hirakata, H. Kanai, K. Fukuda, K. Tsuruya, I. Ishida, Michiaki Kubo, T. Hirano, E. Hirakata, Y. Kuwabara, M. Fujishima

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: Although hematocrit (Ht) around 33 to 36% has been recommended, Ht of 30% is usually achieved as a target level during recombinant human erythropoletin (rHuEPO) therapy in the majority of hemodialysis (HD) patients. The present study aimed at estimating an optimal hematocrit (Ht) for the maximum oxygen delivery to the brain with rHuEPO. Patients and methods: Oxygen delivery was defined as a product of cerebral blood flow and arterial oxygen content (CaO2). The regional cerebral blood flow (rCBF) in each region of interest was measured by positron emission tomography and CaO2 was calculated from hemoglobin concentration, arterial oxygen saturation, and arterial oxygen tension before and after rHuEPO therapy (1500 units, 3 times a week) in 5 HD patients (the mean age of 52 ± 2 (SEM) years old and the mean HD duration of 98 ± 21 months). Results: Ht rose significantly from 21 ± 1 to 31 ± 1% (p < 0.001) after the 3-month rHuEPO treatment in association with a significant increase in CaO2 from 7.7 ± 0.4 to 11.6 ± 0.3 ml O2/100 ml (p < 0.01). Hemispheric rCBF decreased significantly from 40 ± 3 to 32 ± 1 ml/100 g/min (p < 0.02). In all data both before and after rHuEPO treatment, Ht inversely correlated with the hemispheric rCBF (y = 55.7 - 0.76 x, where y is rCBF and x is Ht, r = -0.80, p < 0.01), and positively with CaO2 (y = 0.85 + 0.34 x, where y is CaO2 and x is Ht, r = 0.95, p < 0.01). By using these correlations, the hemispheric oxygen delivery was expressed as a function of Ht, being y = 47.3 + 18.3 x - 0.3 x2, where y is cerebral oxygen delivery and x is Ht. From this curve, Ht at the highest cerebral oxygen delivery in the hemisphere, i.e. an optimal Ht was found to be 35.2%. Above this level of Ht, the hemispheric cerebral oxygen delivery would rather decline. Conclusion: The present study indicated that Ht of about 35% is required for a better oxygen delivery to the brain metabolism during anemia correction with rHuEPO.

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalClinical Nephrology
Volume53
Issue number5
Publication statusPublished - 30-05-2000
Externally publishedYes

Fingerprint

Erythropoietin
Hematocrit
Renal Dialysis
Oxygen
Cerebrovascular Circulation
Brain
Regional Blood Flow
Therapeutics
Positron-Emission Tomography
Anemia
Arterial Pressure
Hemoglobins

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Hirakata, H., Kanai, H., Fukuda, K., Tsuruya, K., Ishida, I., Kubo, M., ... Fujishima, M. (2000). Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clinical Nephrology, 53(5), 354-361.
Hirakata, H. ; Kanai, H. ; Fukuda, K. ; Tsuruya, K. ; Ishida, I. ; Kubo, Michiaki ; Hirano, T. ; Hirakata, E. ; Kuwabara, Y. ; Fujishima, M. / Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. In: Clinical Nephrology. 2000 ; Vol. 53, No. 5. pp. 354-361.
@article{bbfeddbcec1f4a948fc3090b4fbb60eb,
title = "Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients",
abstract = "Aim: Although hematocrit (Ht) around 33 to 36{\%} has been recommended, Ht of 30{\%} is usually achieved as a target level during recombinant human erythropoletin (rHuEPO) therapy in the majority of hemodialysis (HD) patients. The present study aimed at estimating an optimal hematocrit (Ht) for the maximum oxygen delivery to the brain with rHuEPO. Patients and methods: Oxygen delivery was defined as a product of cerebral blood flow and arterial oxygen content (CaO2). The regional cerebral blood flow (rCBF) in each region of interest was measured by positron emission tomography and CaO2 was calculated from hemoglobin concentration, arterial oxygen saturation, and arterial oxygen tension before and after rHuEPO therapy (1500 units, 3 times a week) in 5 HD patients (the mean age of 52 ± 2 (SEM) years old and the mean HD duration of 98 ± 21 months). Results: Ht rose significantly from 21 ± 1 to 31 ± 1{\%} (p < 0.001) after the 3-month rHuEPO treatment in association with a significant increase in CaO2 from 7.7 ± 0.4 to 11.6 ± 0.3 ml O2/100 ml (p < 0.01). Hemispheric rCBF decreased significantly from 40 ± 3 to 32 ± 1 ml/100 g/min (p < 0.02). In all data both before and after rHuEPO treatment, Ht inversely correlated with the hemispheric rCBF (y = 55.7 - 0.76 x, where y is rCBF and x is Ht, r = -0.80, p < 0.01), and positively with CaO2 (y = 0.85 + 0.34 x, where y is CaO2 and x is Ht, r = 0.95, p < 0.01). By using these correlations, the hemispheric oxygen delivery was expressed as a function of Ht, being y = 47.3 + 18.3 x - 0.3 x2, where y is cerebral oxygen delivery and x is Ht. From this curve, Ht at the highest cerebral oxygen delivery in the hemisphere, i.e. an optimal Ht was found to be 35.2{\%}. Above this level of Ht, the hemispheric cerebral oxygen delivery would rather decline. Conclusion: The present study indicated that Ht of about 35{\%} is required for a better oxygen delivery to the brain metabolism during anemia correction with rHuEPO.",
author = "H. Hirakata and H. Kanai and K. Fukuda and K. Tsuruya and I. Ishida and Michiaki Kubo and T. Hirano and E. Hirakata and Y. Kuwabara and M. Fujishima",
year = "2000",
month = "5",
day = "30",
language = "English",
volume = "53",
pages = "354--361",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "5",

}

Hirakata, H, Kanai, H, Fukuda, K, Tsuruya, K, Ishida, I, Kubo, M, Hirano, T, Hirakata, E, Kuwabara, Y & Fujishima, M 2000, 'Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients', Clinical Nephrology, vol. 53, no. 5, pp. 354-361.

Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. / Hirakata, H.; Kanai, H.; Fukuda, K.; Tsuruya, K.; Ishida, I.; Kubo, Michiaki; Hirano, T.; Hirakata, E.; Kuwabara, Y.; Fujishima, M.

In: Clinical Nephrology, Vol. 53, No. 5, 30.05.2000, p. 354-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients

AU - Hirakata, H.

AU - Kanai, H.

AU - Fukuda, K.

AU - Tsuruya, K.

AU - Ishida, I.

AU - Kubo, Michiaki

AU - Hirano, T.

AU - Hirakata, E.

AU - Kuwabara, Y.

AU - Fujishima, M.

PY - 2000/5/30

Y1 - 2000/5/30

N2 - Aim: Although hematocrit (Ht) around 33 to 36% has been recommended, Ht of 30% is usually achieved as a target level during recombinant human erythropoletin (rHuEPO) therapy in the majority of hemodialysis (HD) patients. The present study aimed at estimating an optimal hematocrit (Ht) for the maximum oxygen delivery to the brain with rHuEPO. Patients and methods: Oxygen delivery was defined as a product of cerebral blood flow and arterial oxygen content (CaO2). The regional cerebral blood flow (rCBF) in each region of interest was measured by positron emission tomography and CaO2 was calculated from hemoglobin concentration, arterial oxygen saturation, and arterial oxygen tension before and after rHuEPO therapy (1500 units, 3 times a week) in 5 HD patients (the mean age of 52 ± 2 (SEM) years old and the mean HD duration of 98 ± 21 months). Results: Ht rose significantly from 21 ± 1 to 31 ± 1% (p < 0.001) after the 3-month rHuEPO treatment in association with a significant increase in CaO2 from 7.7 ± 0.4 to 11.6 ± 0.3 ml O2/100 ml (p < 0.01). Hemispheric rCBF decreased significantly from 40 ± 3 to 32 ± 1 ml/100 g/min (p < 0.02). In all data both before and after rHuEPO treatment, Ht inversely correlated with the hemispheric rCBF (y = 55.7 - 0.76 x, where y is rCBF and x is Ht, r = -0.80, p < 0.01), and positively with CaO2 (y = 0.85 + 0.34 x, where y is CaO2 and x is Ht, r = 0.95, p < 0.01). By using these correlations, the hemispheric oxygen delivery was expressed as a function of Ht, being y = 47.3 + 18.3 x - 0.3 x2, where y is cerebral oxygen delivery and x is Ht. From this curve, Ht at the highest cerebral oxygen delivery in the hemisphere, i.e. an optimal Ht was found to be 35.2%. Above this level of Ht, the hemispheric cerebral oxygen delivery would rather decline. Conclusion: The present study indicated that Ht of about 35% is required for a better oxygen delivery to the brain metabolism during anemia correction with rHuEPO.

AB - Aim: Although hematocrit (Ht) around 33 to 36% has been recommended, Ht of 30% is usually achieved as a target level during recombinant human erythropoletin (rHuEPO) therapy in the majority of hemodialysis (HD) patients. The present study aimed at estimating an optimal hematocrit (Ht) for the maximum oxygen delivery to the brain with rHuEPO. Patients and methods: Oxygen delivery was defined as a product of cerebral blood flow and arterial oxygen content (CaO2). The regional cerebral blood flow (rCBF) in each region of interest was measured by positron emission tomography and CaO2 was calculated from hemoglobin concentration, arterial oxygen saturation, and arterial oxygen tension before and after rHuEPO therapy (1500 units, 3 times a week) in 5 HD patients (the mean age of 52 ± 2 (SEM) years old and the mean HD duration of 98 ± 21 months). Results: Ht rose significantly from 21 ± 1 to 31 ± 1% (p < 0.001) after the 3-month rHuEPO treatment in association with a significant increase in CaO2 from 7.7 ± 0.4 to 11.6 ± 0.3 ml O2/100 ml (p < 0.01). Hemispheric rCBF decreased significantly from 40 ± 3 to 32 ± 1 ml/100 g/min (p < 0.02). In all data both before and after rHuEPO treatment, Ht inversely correlated with the hemispheric rCBF (y = 55.7 - 0.76 x, where y is rCBF and x is Ht, r = -0.80, p < 0.01), and positively with CaO2 (y = 0.85 + 0.34 x, where y is CaO2 and x is Ht, r = 0.95, p < 0.01). By using these correlations, the hemispheric oxygen delivery was expressed as a function of Ht, being y = 47.3 + 18.3 x - 0.3 x2, where y is cerebral oxygen delivery and x is Ht. From this curve, Ht at the highest cerebral oxygen delivery in the hemisphere, i.e. an optimal Ht was found to be 35.2%. Above this level of Ht, the hemispheric cerebral oxygen delivery would rather decline. Conclusion: The present study indicated that Ht of about 35% is required for a better oxygen delivery to the brain metabolism during anemia correction with rHuEPO.

UR - http://www.scopus.com/inward/record.url?scp=17144447526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144447526&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 354

EP - 361

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 5

ER -